Oveporexton

What is Oveporexton?#

Oveporexton (TAK-861, also known as suntinorexton) is a first-in-class oral orexin receptor 2 (OX2R)-selective small molecule agonist developed by Takeda Pharmaceutical Company for the treatment of narcolepsy type 1 (NT1). Unlike traditional narcolepsy therapies that manage symptoms, oveporexton is designed to address the root cause of NT1 by directly restoring orexin signaling lost due to autoimmune destruction of hypothalamic orexin-producing (hypocretin) neurons.

Narcolepsy type 1 is caused by a severe deficiency of orexin (also called hypocretin), a neuropeptide produced by a small cluster of neurons in the lateral hypothalamus. These neurons are selectively destroyed in an autoimmune process, resulting in loss of the wake-stabilizing orexin signal. Oveporexton selectively activates OX2R, the receptor subtype primarily responsible for wakefulness promotion and REM sleep regulation.

Mechanism of Action#

Oveporexton activates OX2R with a half-maximal effective concentration (EC50) of 2.5 nM in calcium mobilization assays, with approximately 3000-fold selectivity over OX1R. This high selectivity is designed to restore wakefulness without the off-target effects associated with OX1R activation.

Downstream Signaling#

Oveporexton activates OX2R downstream signaling pathways in a manner similar to endogenous orexin peptides:

• IP1 accumulation: EC50 of 1.2 nM, indicating potent Gq-coupled phospholipase C activation
• Beta-arrestin recruitment: EC50 of 30 nM
• ERK1/2 phosphorylation: EC50 of 34 nM, supporting neuronal survival and plasticity signaling
• CREB phosphorylation: EC50 of 3.6 nM, promoting transcriptional regulation of wakefulness-related genes

Neuronal Activation#

Oveporexton induces dose-dependent membrane depolarization in histaminergic neurons of the tuberomammillary nucleus (TMN), a key arousal center, with an EC50 of 31.7 nM. Preclinical studies demonstrated brain-wide neuronal activation patterns highly correlated with those produced by endogenous orexin, suggesting efficient engagement of the natural wakefulness circuitry.

Comparison to TAK-994 (Danavorexton)#

Oveporexton is approximately 10-fold more potent than TAK-994 (danavorexton), Takeda's first-generation OX2R agonist that was discontinued due to hepatotoxicity in Phase 2. Oveporexton has shown no hepatotoxic effects in clinical trials, representing a significant improvement in the safety profile of this drug class.

Research Overview#

Oveporexton has been evaluated in a comprehensive clinical development program:

• Preclinical studies: Demonstrated wakefulness promotion in monkeys and improvement of narcolepsy-like phenotypes in orexin-deficient mouse models (Scientific Reports, 2024)
• Phase 2b trial: Published in the New England Journal of Medicine (May 2025), showing significant improvements in MWT, ESS, and cataplexy across all dose groups (n=112)
• Phase 3 FirstLight (TAK-861-3001): 168 participants randomized to high dose, low dose, or placebo across 19 countries; all primary and secondary endpoints met
• Phase 3 RadiantLight (TAK-861-3002): 105 participants in high-dose and placebo arms; all endpoints met
• NDA filing: FDA accepted with Priority Review in February 2026; PDUFA date in Q3 2026

Important Considerations#

• Oveporexton is an investigational drug and is not yet approved by any regulatory authority
• Most common adverse events are insomnia (43-48%), urinary urgency (30-33%), and urinary frequency (29-32%)
• Clinical trial data is specific to narcolepsy type 1; efficacy in other sleep disorders is not established
• Not a peptide in the traditional sense but a small molecule orexin receptor agonist
• Requires medical evaluation and diagnosis of narcolepsy before use

Key Research Findings#

Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1, published in New England Journal of Medicine (Dauvilliers Y et al., 2025; PMID: 40367374):

• The study showed MWT improvement of 12.5 to 25.4 minutes across dose groups vs -1.2 minutes placebo

TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models, published in Scientific Reports (Mitsukawa K et al., 2024; PMID: 39242684):

• The study showed OX2R EC50 of 2.5 nM with approximately 3000-fold selectivity over OX1R

Related Reading#

• Oveporexton research studies and evidence
• Oveporexton dosing protocols
• Oveporexton side effects profile
• Cortistatin research guide
• DSIP research guide